HuniLife Biotechnology Inc. and Shimadzu Corporation signed a technology transfer agreement of Lactosome in November 2016.
The Lactosome technology was developed by Kyoto University and Shimadzu Corporation, a leading Japanese company in the field of medical equipment and analytical instruments. Currently, Shimadzu has about 11,000 employees worldwide with annual sales of ¥342,236,000,000 in 2016.
“We are thrilled to have the opportunity to collaborate with Shimadzu Corporation in developing novel cancer drugs for medical care”, said Dr. Ying-Jye Wu, Chairman and CEO of HuniLife. “This collaboration has created an excellent synergy by employing the expertise in drug development of HuniLife and the proprietary Lactosome technology of Shimadzu Corporation. We strongly believe that Lactosome technology in drug development will enhance the drug efficacy and reduce toxicity in treating patients. We are looking forward to a productive and prosperous collaboration”.
HuniLife Biotechnology, Inc.,
HuniLife Biotechnology, Inc., was established in December 2013. The company is headquartered in Neihu Sciences Park, Taipei City, Taiwan. Its management team and scientists have a wealth of experience in drug development in biopharmaceutical industry. The company’s main focus is to develop new drugs for the treatment of cancer and immune diseases.
In 2015, the company licensed a novel monoclonal antibody, HuL001, from the Development Center for Biotechnology (DCB) and National Health Research Institute (NHRI). This unique antibody acts on ENO1 molecule that is expressed only on the activated macrophages. Thus, it can be used to treat immune diseases such as multiple sclerosis and rheumatoid arthritis by activated macrophages. Currently, HuL001 project is at the preclinical stage and is expected to enter the clinical trial Phase I in early 2018.
Shimadzu Corporation
Shimadzu Corporation was founded in Kyoto, Japan, in 1815. Its corporate philosophy is to contribute to community through innovative science and technology. For the past 140 years since its foundation, Shimadzu has continued to develop analytical instruments and medical equipment for medical research, product development, and quality control in a variety of fields. Shimadzu Corporation has become a major global provider of analytical and medical instruments. In 2002, a longstanding employee, Koichi Tanake, won the Nobel Prize in chemistry.
Currently, Shimadzu Corporation has 11,000 employees working at headquarters and branch offices worldwide. The annual revenue in 2016 has reached ¥342,236,000,000..